OBJECTIVE: Imbalance between alpha(1)-antitrypsin and neutrophil elastase is an underlying cause of lung tissue damage that may create a favorable host environment for carcinogenesis. We conducted a case-control study to investigate whether genetic variations indicative of alpha(1)-antitrypsin deficiency (A1ATD) or an excess of neutrophil elastase modify lung cancer risk DESIGN: The case patients were 305 consecutively identified primary lung cancer patients, and the control subjects were 338 community residents. Protease inhibitor-1 (PI1), encoding alpha(1)-antitrypsin, was typed by an isoelectric focusing assay. Neutrophil elastase-2 (ELA2), encoding neutrophil elastase, was typed by two single-nucleotide polymorphism sites. Multivariable logistic regression models tested the independent and interactive effects of PI1, ELA2, tobacco smoke exposure, COPD, and family history of lung cancer RESULTS: Sex and ethnicity were comparable between case patients and control subjects, but case patients were more likely to be smokers, and to have a history of COPD, environmental tobacco smoke exposure, and a positive family history of lung cancer. Haplotype analysis indicated an overall strong association between the two ELA2 markers and lung cancer risk. Our best-fitting model showed significant and independent effects of the PI1-deficient allele (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.4 to 3.0) and the ELA2 T-G haplotype (OR, 4.1; 95% CI, 1.9 to 8.9) on lung cancer risk, and an increased risk (OR, 2.6; 95% CI, 2.4 to 2.8) for individuals carrying both a PI1-deficient allele and a G-G haplotype CONCLUSIONS: Genotypes indicative of A1ATD and/or an excess of neutrophil elastase are significantly associated with lung cancer risk. Our findings may provide opportunities to better understand the mechanisms of lung cancer development and risk reduction.
OBJECTIVE: Imbalance between alpha(1)-antitrypsin and neutrophil elastase is an underlying cause of lung tissue damage that may create a favorable host environment for carcinogenesis. We conducted a case-control study to investigate whether genetic variations indicative of alpha(1)-antitrypsin deficiency (A1ATD) or an excess of neutrophil elastase modify lung cancer risk DESIGN: The case patients were 305 consecutively identified primary lung cancerpatients, and the control subjects were 338 community residents. Protease inhibitor-1 (PI1), encoding alpha(1)-antitrypsin, was typed by an isoelectric focusing assay. Neutrophil elastase-2 (ELA2), encoding neutrophil elastase, was typed by two single-nucleotide polymorphism sites. Multivariable logistic regression models tested the independent and interactive effects of PI1, ELA2, tobacco smoke exposure, COPD, and family history of lung cancer RESULTS: Sex and ethnicity were comparable between case patients and control subjects, but case patients were more likely to be smokers, and to have a history of COPD, environmental tobacco smoke exposure, and a positive family history of lung cancer. Haplotype analysis indicated an overall strong association between the two ELA2 markers and lung cancer risk. Our best-fitting model showed significant and independent effects of the PI1-deficient allele (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.4 to 3.0) and the ELA2 T-G haplotype (OR, 4.1; 95% CI, 1.9 to 8.9) on lung cancer risk, and an increased risk (OR, 2.6; 95% CI, 2.4 to 2.8) for individuals carrying both a PI1-deficient allele and a G-G haplotype CONCLUSIONS: Genotypes indicative of A1ATD and/or an excess of neutrophil elastase are significantly associated with lung cancer risk. Our findings may provide opportunities to better understand the mechanisms of lung cancer development and risk reduction.
Authors: Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: Haris G Vikis; Andrew E Gelman; Andrew Franklin; Lauren Stein; Amy Rymaszewski; Jihong Zhu; Pengyuan Liu; Jay W Tichelaar; Alexander S Krupnick; Ming You Journal: Mol Carcinog Date: 2011-10-17 Impact factor: 4.784
Authors: Lindsey Enewold; Leah E Mechanic; Elise D Bowman; Elizabeth A Platz; Anthony J Alberg Journal: Anticancer Res Date: 2012-09 Impact factor: 2.480
Authors: Michał Kistowski; Janusz Dębski; Jakub Karczmarski; Agnieszka Paziewska; Jacek Olędzki; Michał Mikula; Jerzy Ostrowski; Michał Dadlez Journal: Mol Cell Proteomics Date: 2016-12-07 Impact factor: 5.911
Authors: Aleksandra Topic; Mila Ljujic; Aleksandra Nikolic; Natasa Petrovic-Stanojevic; Vesna Dopudja-Pantic; Marija Mitic-Milikic; Dragica Radojkovic Journal: Pathol Oncol Res Date: 2010-06-03 Impact factor: 3.201
Authors: Antonio Sica; Chiara Porta; Sara Morlacchi; Stefania Banfi; Laura Strauss; Monica Rimoldi; Maria Grazia Totaro; Elena Riboldi Journal: Cancer Microenviron Date: 2011-09-24
Authors: Joanna L Richens; Richard A Urbanowicz; Elizabeth A M Lunt; Rebecca Metcalf; Jonathan Corne; Lucy Fairclough; Paul O'Shea Journal: Respir Res Date: 2009-04-22
Authors: Antonello Punturieri; Eva Szabo; Thomas L Croxton; Steven D Shapiro; Steven M Dubinett Journal: J Natl Cancer Inst Date: 2009-04-07 Impact factor: 13.506
Authors: Laura M Beaver; Erik J Stemmy; Arnold M Schwartz; Jesse M Damsker; Stephanie L Constant; Susan M Ceryak; Steven R Patierno Journal: Environ Health Perspect Date: 2009-08-19 Impact factor: 9.031